Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The main drug-drug interactions associated with pazopanib include

CYP3A4 Inhibitors/Inducers

CYP3A4 Inhibitors1,2

Co-administration of strong CYP3A4 inhibitors increases pazopanib concentrations. Concomitant ketoconazole increased the mean pazopanib AUC(0-24) and Cmax by 66% and 45%, respectively, relative to pazopanib alone.2

QT prolongators

QTc Interval-Prolonging Drugs

QT prolongation and Torsade de Pointes has been reported with pazopanib; use with caution in patients taking anti-arrhythmic drugs or other drugs that may prolong the QT interval.2

Other Drug-drug Interactions

P-glycoprotein and BCRP Inhibitors1,2

Strong inhibitors of P-gp and BCRP may increase exposure to pazopanib.1 Co-administration of 1500 mg lapatinib (a weak inhibitor of CYP3A4 and P-gp and a potent BCRP inhibitor) with 800 mg pazopanib increased the mean pazopanib AUC(0-24) and Cmax by 50-60% compared to pazopanib alone.1,2 Co-administration with potent P-gp or BCRP inhibitors may alter the distribution of pazopanib, including distribution into the central nervous systems (CNS).2

CYP3A4, P-gp, and BCRP Inducers1,2

CYP3A4 inducers such as rifampicin may decrease plasma pazopanib concentrations. Co-administration of pazopanib with strong P-gp or BCRP inducers may alter the exposure and distribution of pazopanib, including distribution into the CNS.2

CYP3A4, CYP2D6, and CYP2C8 Substrates

Co-administration of pazopanib led to an increase of ~30% in the mean AUC and Cmax of midazolam (CYP3A4 substrate); increases of 33-64% in the ratio of dextrometrophan to dextrophan in the urine after oral administration of dextromethorphan (CYP2D6 substrate); and increases of 25%-31% in the AUC and Cmax of paclitaxel (CYP3A4 and CYP2C8 substrate).1,2

UGT1A1 and OATP1B1 Substrates

Pazopanib may increase concentrations of drugs eliminated by UGT1A1 (uridine diphosphoglucuronosyl-transferase 1A1) and OATP1B1 (organic anion transporting polypeptide).1,2

Co-administration of pazopanib 400 mg/day with cetuximab 250 mg/m2 and irinotecan 150 mg/m2 resulted in an increase of ~20% in systemic exposure to SN-38 (the active metabolite of irinotecan, and a substrate for UGT1A1 and OATP1B1).2

In a meta-analysis, ALT > 3x ULN was reported in 27% of patients given concomitant pazopanib and simvastatin, compared with 14% of those who did not use statins (p = 0.038). Statins are OATP1B1 substrates.1,2

Medicines that Raise Gastric pH

Pazopanib exhibits pH-dependent solubility.1 Co-administration of pazopanib and esomeprazole decreased the bioavailability of pazopanib by approximately 40% (AUC and Cmax).1,2


  1. Food and Drug Administration. Pazopanib (VOTRIENT) Prescribing information. 2015.
  2. European Medicines Agency. Pazopanib (VOTRIENT) Summary of Product Characteristics. 2015.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.